EGFR and neoplasm: In our cohort, after adjusting for patient characteristics, treatments, and other tumor genetic alterations, we observed that while CDKN2A and CDKN2B deletions were associated with worse survival, EGFR amplification was not correlated with poor outcomes (Fig. 2; Table 3).